Since the advent of highly active antiretroviral therapy (HAART), patients infected with human immunodeficiency virus-1 (HIV-1) are living longer lives. However, HIV-1-positive (HIV-1+) patients are now experiencing many non-AIDS related comorbidities including myocardial infarction, atherosclerotic lesions, and other preclinical markers of atherosclerosis including increased carotid intima-media thickness (cIMT), arterial stiffness, and impaired flow-mediated dilation (FMD). Studies have implicated the virus, the treatment, or both in the progression of these co-morbidities, causing the exact mechanisms of cardiovascular disease progression to remain unclear.
- Bioengineering Division
Treatment With Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Leads to Increase of Carotid Intima-Media Thickness in Mice
- Views Icon Views
- Share Icon Share
- Search Site
Caulk, AW, & Gleason, RL, Jr. "Treatment With Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Leads to Increase of Carotid Intima-Media Thickness in Mice." Proceedings of the ASME 2013 Summer Bioengineering Conference. Volume 1A: Abdominal Aortic Aneurysms; Active and Reactive Soft Matter; Atherosclerosis; BioFluid Mechanics; Education; Biotransport Phenomena; Bone, Joint and Spine Mechanics; Brain Injury; Cardiac Mechanics; Cardiovascular Devices, Fluids and Imaging; Cartilage and Disc Mechanics; Cell and Tissue Engineering; Cerebral Aneurysms; Computational Biofluid Dynamics; Device Design, Human Dynamics, and Rehabilitation; Drug Delivery and Disease Treatment; Engineered Cellular Environments. Sunriver, Oregon, USA. June 26–29, 2013. V01AT04A025. ASME. https://doi.org/10.1115/SBC2013-14744
Download citation file: